| Autor: |
Wong, Michael, Gain, Chandrima, Sharma, Madhav B, Abadi, Leila Fotooh, Hugo, Cristelle, Vassilopoulos, Hariclea, Daskou, Maria, Fishbein, Gregory A, Kelesidis, Theodoros |
| Předmět: |
|
| Zdroj: |
Journal of Infectious Diseases; 5/15/2024, Vol. 229 Issue 5, p1372-1381, 10p |
| Abstrakt: |
Background Altered mediators of airway tissue remodeling such as matrix metalloproteinases (MMPs) in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may contribute to morbidity in coronavirus disease 2019 (COVID-19); however, the differential impact of SARS-CoV-2 variants of concern (VOCs) on MMPs is unknown. Methods Using both in vitro human airway cell culture model and in vivo transgenic mouse model of SARS-CoV-2 infection, we studied the differential effect of SARS-CoV-2 VOCs on expression of key MMPs and inflammatory mediators in airway cells and tissues. Results The most consistent findings with all SARS-CoV-2 variants in infected compared to uninfected human bronchial epithelial cell air–liquid interface cultures were the SARS-CoV-2–induced increases in MMP-12 and tissue inhibitor of MMPs. Infection with both SARS-CoV-2 wild type and SARS-CoV-2 Delta variant over 3 days postinfection (dpi) and with Beta variant over 7 dpi increased lung tissue levels of MMP-9 compared to uninfected mice. Overall, SARS-CoV-2 variants had differential dose-dependent impact on secretion of MMP-1, MMP-2, MMP-9, and MMP-12 that varied at the protein versus the gene level and in the early noninflammatory compared to late inflammatory phase of infection. Conclusions We provide novel mechanistic insight that the differential impact of SARS-CoV-2 variants on severity of COVID-19 may partially be attributed to unique changes in MMPs. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
